Compare Medpace Holdings Inc (MEDP) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while abrdn Physical Palladium Shares ETF trades at $20.77 (market cap $586.03M). The key difference: Medpace Holdings Inc is far larger — about 28.7× abrdn Physical Palladium Shares ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| MEDP | PALL | |
|---|---|---|
Market Cap | $16.82B | $586.03M |
Volume | 223,093 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $630.19 | $37.18 |
52-Week Low | $393.42 | $20.30 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
PALL trades at $20.49, up 0.94% today, but faces strong bearish technical signals with 13 of 13 moving averages indicating sell signals. The ETF shows oversold conditions with RSI readings below 13, suggesting potential for a technical bounce. Recent news highlights palladium's underperformance relative to other precious metals, with some analysts viewing current weakness as a buying opportunity given supply risks and industrial demand fundamentals.
The outlook remains challenging with bearish technical momentum, though oversold conditions may provide short-term relief. Investment opportunity exists if palladium prices recover from current depressed levels, supported by supply constraints and industrial demand. Key risks include continued commodity price volatility and broader precious metals market dynamics that could pressure the ETF further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
